The Deteriorating Head-Injured Patient on Antiplatelets
A 74-year-old man on aspirin 81 mg and clopidogrel (last dose 30 hours ago, for a drug-eluting coronary stent placed 4 months ago) is brought in after a fall down six stairs. GCS is 14 (E4 V4 M6), pupils 3 mm and reactive, no focal deficit. Non-contrast CT shows a 6 mm left frontal contusion and a thin left convexity subdural haematoma with 4 mm midline shift. He is on a cardiology-maintained dual antiplatelet regimen; the stent was placed for an acute coronary syndrome. Repeat CT at 6 hours shows the contusion has grown to 18 mm with surrounding oedema and midline shift now 7 mm; GCS has dropped to 12 (E3 V4 M5). He is haemodynamically stable, platelets 190, INR 1.0.
1. How do you weigh the risks of reversing his antiplatelet therapy against the risk of coronary stent thrombosis, and what is your immediate management plan?
Read the worked answer
Framing the conflict. Two competing catastrophes: (1) expansion of a traumatic intraparenchymal haemorrhage with falling GCS and rising midline shift, and (2) stent thrombosis if both antiplatelet agents are stopped abruptly, particularly in the first 6 months after a drug-eluting stent for ACS. The radiologic and clinical trajectory (contusion 6→18 mm, shift 4→7 mm, GCS 14→12) indicates active haemorrhagic progression, which is the more immediate and more likely threat over the next 24–72 hours.
Decision. Prioritise control of the intracranial bleeding. Stop both antiplatelet agents. Do not give platelet transfusion reflexively for a small/stable lesion, but here progression plus planned surgery justifies platelet support: give 1 adult dose of platelets (or DDAVP 0.3 mcg/kg IV as an adjunct) and consider platelet function testing/viscoelastic guidance if available. There is no role for recombinant factor VIIa outside trials.
Surgical judgement. The lesion is a growing contusion with mass effect and neurologic decline - a decompressive craniectomy (or craniotomy with duralplasty and evacuation of the contusion) is reasonable. A key point: the subdural is thin; the driver is the contusion. A large decompressive flap reduces the need for aggressive intraparenchymal dissection.
Cardiology co-management. Notify cardiology immediately. Aspirin is usually the first agent to restart (typically within 24–72 h once haemostasis is secure and repeat imaging is stable); clopidogrel resumption is a joint decision. The stent is 4 months old - still within the highest-risk window - so document the explicit risk discussion. If the patient were unstable or the lesion unsalvageable, a conservative pathway with close neuro-observations and serial CT would be defensible; the falling GCS tips the balance to intervention.
Monitoring. ICP monitor if GCS ≤8 or after surgery; strict BP control (SBP <140), reverse any coagulopathy, serial CT at 6–12 h and after any change.
2. Two days post-operatively the patient develops chest pain and ST changes. How does this alter your antithrombotic strategy, and what safeguards do you put in place?
Read the worked answer
Recognition. New chest pain with ischaemic ECG changes in a post-craniotomy patient on no antiplatelets is a presumed acute coronary syndrome until proven otherwise - get troponin, ECG, and cardiology at the bedside. This is the feared complication of the earlier decision and must be managed as a team, not unilaterally.
Strategy. If there is ST-elevation or haemodynamic instability, the coronary risk dominates and antiplatelet/anticoagulant therapy must be restarted, accepting the intracranial risk. If it is NSTEMI, individualise: restart aspirin (the lower-bleeding-risk agent) and consider a glycoprotein IIb/IIIa or clopidogrel load only after cardiology agrees and with a recent CT confirming a stable operative bed.
Safeguards. (1) Repeat CT before restarting potent antithrombotics to confirm no rebleeding. (2) Restart the lowest effective antithrombotic burden first (aspirin alone). (3) Keep the patient in a monitored bed with frequent neuro checks; a low threshold for repeat imaging. (4) Document a shared, named-consultant decision with the family about the trade-off. (5) If PCI is required, prefer balloon angioplasty/bare-metal strategy to shorten the mandated dual-antiplatelet duration, in discussion with interventional cardiology.
Teaching point. The exam wants you to show you can re-litigate the risk balance as new information arrives, rather than applying a fixed rule. Neither 'never stop antiplatelets' nor 'always reverse' is correct; the answer is a time-critical, team-based, imaging-guided sequence.